Pcna-I1 is , while it's Molecular Formula is C17H14N2O2S. Used in Cancer Treatment: PCNA-I1 is used as an anticancer agent for its selective toxicity towards cancer cells over non-transformed cells. It exhibits potent inhibitory effects on the growth of a variety of human and mouse cancer cell lines, with IC50s ranging from 0.05-0.3 μM for cancer cells and 0.99-2 μM for non-transformed cells. PCNA-I1's ability to arrest the cell cycle at different phases makes it a promising candidate for cancer treatment. Used in Cell Cycle Regulation Research: PCNA-I1 is used as a research tool for studying cell cycle regulation, particularly in the context of cancer cell proliferation. Its ability to accumulate cells in the G1 phase and halt the cell cycle in the S and G2/M phases provides valuable insights into the mechanisms underlying cell cycle control and the potential for therapeutic intervention. Used in Preclinical Cancer Models: PCNA-I1 is used in preclinical cancer models, such as the LNCaP prostate cancer mouse xenograft model, to evaluate its efficacy in reducing tumor growth. When administered at a dose of 10 mg/kg, five days per week, for two weeks, PCNA-I1 has demonstrated a significant reduction in tumor growth, supporting its potential as a therapeutic agent in cancer treatment. Used in Drug Development: PCNA-I1 serves as a lead compound in the development of novel anticancer drugs targeting the proliferating cell nuclear antigen (PCNA). Its selective toxicity, cell cycle arrest properties, and tumor growth reduction in preclinical models make it a valuable starting point for the design and optimization of new cancer therapeutics.

What is the CAS number for Pcna-I1?

The CAS number of Pcna-I1 is 444930-42-1.

What is Pcna-I1 (444930-42-1) used for?

PCNA-I1 is an inhibitor of proliferating cell nuclear antigen (PCNA) that binds to PCNA trimers (Kd = 0.41 μM) and dose-dependently reduces the level of PCNA associated with chromatin in PC3 cells. It preferentially inhibits growth of a variety of human and mouse cancer cell lines (IC50s = 0.05-0.3 μM) over non-transformed cells (IC50s = 0.99-2 μM). PCNA-I1 leads to an accumulation of cells in the G1 phase during the first 24 hours of incubation and halts the cell cycle in the S and G2/M phases by 72 hours following treatment. It also reduces tumor growth in an LNCaP prostate cancer mouse xenograft model when administered at a dose of 10 mg/kg, five days per week, for two weeks.

Pcna-I1 is , while it's Molecular Formula is C17H14N2O2S. Used in Cancer Treatment: PCNA-I1 is used as an anticancer agent for its selective toxicity towards cancer cells over non-transformed cells. It exhibits potent inhibitory effects on the growth of a variety of human and mouse cancer cell lines, with IC50s ranging from 0.05-0.3 μM for cancer cells and 0.99-2 μM for non-transformed cells. PCNA-I1's ability to arrest the cell cycle at different phases makes it a promising candidate for cancer treatment. Used in Cell Cycle Regulation Research: PCNA-I1 is used as a research tool for studying cell cycle regulation, particularly in the context of cancer cell proliferation. Its ability to accumulate cells in the G1 phase and halt the cell cycle in the S and G2/M phases provides valuable insights into the mechanisms underlying cell cycle control and the potential for therapeutic intervention. Used in Preclinical Cancer Models: PCNA-I1 is used in preclinical cancer models, such as the LNCaP prostate cancer mouse xenograft model, to evaluate its efficacy in reducing tumor growth. When administered at a dose of 10 mg/kg, five days per week, for two weeks, PCNA-I1 has demonstrated a significant reduction in tumor growth, supporting its potential as a therapeutic agent in cancer treatment. Used in Drug Development: PCNA-I1 serves as a lead compound in the development of novel anticancer drugs targeting the proliferating cell nuclear antigen (PCNA). Its selective toxicity, cell cycle arrest properties, and tumor growth reduction in preclinical models make it a valuable starting point for the design and optimization of new cancer therapeutics.

What is the CAS number for Pcna-I1?

The CAS number of Pcna-I1 is 444930-42-1.

What is Pcna-I1 (444930-42-1) used for?

PCNA-I1 is an inhibitor of proliferating cell nuclear antigen (PCNA) that binds to PCNA trimers (Kd = 0.41 μM) and dose-dependently reduces the level of PCNA associated with chromatin in PC3 cells. It preferentially inhibits growth of a variety of human and mouse cancer cell lines (IC50s = 0.05-0.3 μM) over non-transformed cells (IC50s = 0.99-2 μM). PCNA-I1 leads to an accumulation of cells in the G1 phase during the first 24 hours of incubation and halts the cell cycle in the S and G2/M phases by 72 hours following treatment. It also reduces tumor growth in an LNCaP prostate cancer mouse xenograft model when administered at a dose of 10 mg/kg, five days per week, for two weeks.

Products

Product classification

small-molecule inhibitor
intermediate
Pharmaceutical intermediate
Biochemical reagent
fire retardant
chemical reagent
ionic liquid
Inhibitor
Antibody
Pesticide
New materials
Customization
Nucleosides
Food additives
Supplement
API
Pharmaceutical intermediates

Contact us

Tel：+86-0533-2185556
Fax：+86-0533-2185556
Phone：WhatsApp: +86 15965530500
Website：https://www.shandonghangyubiotech.com
Email：admin@hangyubiotech.com
Address：Room 2516, Dingcheng Building, Beijing Road, Zhangdian District, Zibo City, Shandong Province

444930-42-1

Product Name:PCNA-I 1
Molecular Formula:C17H14N2O2S
Molecular Weight:310.4

Inquiry

Product Details

Purity:99%

Buy high quality and low price PCNA-I 1 444930-42-1 now

Molecular Formula:C17H14N2O2S
Molecular Weight:310.4
PKA:8.31±0.50(Predicted)

Relevant Products

Prasugrel
CAS：115473-15-9
OXACILLIN SODIUM
CAS：1173-88-2
FPH2
CAS：957485-64-2
D2141
CAS：157-03-9

Home

About us

Products

small-molecule inhibitor

intermediate

Pharmaceutical intermediate

Biochemical reagent

fire retardant

chemical reagent

ionic liquid

Inhibitor

Antibody

Pesticide

New materials

Customization

Nucleosides

Food additives

Supplement

API

Pharmaceutical intermediates

Biological products

Polypeptides

Chemical reagents

Small molecule inhibitors

Organic electronic chemical materials

Technical Support

News

Contact Us